Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
The Prostate · 2025
DOI: 10.1002/pros.24865 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Mitsuhisa Nishimoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan. Hauptthemen laut MEDLINE: Receptors, Androgen, Abiraterone Acetate, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The authors received no specific funding for this work..
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The efficacy of abiraterone acetate varies among patients with high‐risk metastatic castration‐sensitive prostate cancer (mCSPC). Both androgen receptor (AR) and cytokeratin 18 (CK18) are markers of the luminal lineage of prostate cancer, and their expression levels have been suggested to affect the response to androgen deprivation therapy (ADT). This study aimed to predict the efficacy of abiraterone acetate in high‐risk mCSPC via immunohistochemical staining of biopsy specimens obtained at the time of prostate cancer diagnosis.
Methods
We retrospectively analyzed 44 patients treated with abiraterone acetate in combination with ADT. AR and CK18 expression in prostate biopsy specimens were assessed using immunohistochemical staining.
Results
AR and CK18 staining was not significantly associated with overall survival (OS). However, low AR staining was significantly associated with a shorter time to castration‐resistant prostate cancer (TTCRPC) compared with high AR staining (log‐rank test, p = 0.018). Similarly, low CK18 staining was significantly associated with a shorter TTCRPC compared with high CK18 staining (log‐rank test, p = 0.037).
Conclusions
Immunohistochemical analysis of AR or CK18 expression in biopsy specimens may serve as a predictive biomarker of high‐risk mCSPC treated with abiraterone acetate. Trial Registration: None
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.
- Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan.
- Department of Urology, Kindai University Nara Hospital, Ikoma, Japan.
ORCID-Profile: Mitsuhisa Nishimoto, Marco A De Velasco, Yutaka Yamamoto, Saizo Fujimoto, Yasunori Akashi, Shingo Toyoda, Mamoru Hashimoto, Shogo Adomi, Eri Banno, Yoshitaka Saito, Takafumi Minami, Akihide Hirayama, Kazuhiro Yoshimura, Hirotsugu Uemura, Kazutoshi Fujita
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Nishimoto, M., De Velasco, M. A., Yamamoto, Y., Fujimoto, S., Akashi, Y., Toyoda, S., Hashimoto, M., Adomi, S., Banno, E., Saito, Y., Minami, T., Hirayama, A., Yoshimura, K., Uemura, H., & Fujita, K. (2025). Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate. The Prostate. https://doi.org/10.1002/pros.24865
Vancouver
Nishimoto M, De Velasco MA, Yamamoto Y, Fujimoto S, Akashi Y, Toyoda S, et al. Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate. The Prostate. 2025. doi:10.1002/pros.24865
BibTeX
@article{Nishimoto2025,
author = {Nishimoto, Mitsuhisa and De Velasco, Marco A and Yamamoto, Yutaka and Fujimoto, Saizo and Akashi, Yasunori and Toyoda, Shingo and Hashimoto, Mamoru and Adomi, Shogo and Banno, Eri and Saito, Yoshitaka and Minami, Takafumi and Hirayama, Akihide and Yoshimura, Kazuhiro and Uemura, Hirotsugu and Fujita, Kazutoshi},
title = {Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24865}
}
EUVIMED